Get the Stockscreener App
83.04
0.50%
0.41
Pre-market:
83.89
0.85
+1.02%
Edwards Lifesciences Corp stock is traded at $83.04, with a volume of 6.71M.
It is up +0.50% in the last 24 hours and down -8.53% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$82.63
Open:
$83.3
24h Volume:
6.71M
Relative Volume:
1.28
Market Cap:
$47.81B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
45.12
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
-2.31%
1M Performance:
-8.53%
6M Performance:
-0.67%
1Y Performance:
+3.80%
1-Day Range:
$81.16
$84.12
1-Week Range:
$81.16
$89.08
52-Week Range:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
83.04 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
104.49 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Form 4 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com Canada
Edwards Lifesciences CEO Bernard Zovighian sells $245,134 in shares - Investing.com
Form 144 Edwards Lifesciences Corp For: 27 July - Investing.com India
EW|Edwards Lifesciences Corp|Price:83.040|Chg%:+0.410 - TradingKey
Form 144 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com Canada
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion? - Yahoo Finance Singapore
Edwards Lifesciences (EW) insider Zovighian details recent $2.83M stock sale in Form 144 - Stock Titan
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences stock trades steady as TAVR growth supports margins - Ad-hoc-news.de
ETFs Investing in Edwards Lifesciences Corporation Stocks - TradingView
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium - Yahoo Finance
Edwards Lifesciences Corp (EW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edwards Lifesciences Corp (EW) Institutional Confidence - TradingKey
EW|Edwards Lifesciences Corp|Price:82.630|Chg%:-1.185 - TradingKey
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion - MedTech Dive
Why is Edwards Lifesciences stock rallying today? By Investing.com - Investing.com South Africa
Why is Edwards Lifesciences stock rallying today? - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Receives Upgrade from Leerink with New Price Target - GuruFocus
Edwards Lifesciences Reports Strong Q2 2026 Results With 13.6% Sales Growth, Raises Full-Year Guidance - Minichart
Piper Sandler raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Edwards lifts FY26 growth outlook following steady Q2 performance - Yahoo Finance
Edwards Lifesciences Corporatio (EW) Stock Forecasts - Yahoo Finance
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Life - Benzinga
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises - Yahoo Finance
EDWARDS LIFESCIENCES CORP : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $101 FROM $87 - Bitget
Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating - marketscreener.com
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum - Investing.com
Edwards Lifesciences stock holds focus on margin and growth - AD HOC NEWS
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum By Investing.com - Investing.com Canada
Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87 - marketscreener.com
EW|Edwards Lifesciences Corp|Price:83.800|Chg%:-0.570 - TradingKey
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo! Finance Canada
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements - GuruFocus
Edwards Lifesciences Announces Q2 2026 Financial Results Highlighting Market Leadership - Kalkine Media
Edwards Lifesciences (EW) Reports Strong Q2 2026 Sales Growth - GuruFocus
Edwards Lifesciences Q2 Earnings Call Highlights - Yahoo Finance
Edwards Lifesciences earnings up next: TAVR momentum in focus - Investing.com UK
Earnings call transcript: Edwards Lifesciences tops Q2 2026 estimates, lifts sales outlook - Investing.com
Edwards Lifesciences (EW) Reports Strong Q2 Earnings, Raises Rev - GuruFocus
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Edwards Lifesciences Jumps After Strong Q2 Growth and Higher 2026 Sales Outlook - Moomoo
Edwards Lifesciences jumps after strong Q2 growth and higher 2026 sales outlook - Quiver Quantitative
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth - WSJ
Is Edwards Lifesciences (EW) Undervalued After Q2 Earnings Beat? - GuruFocus
Edwards Lifesciences Q2 Adjusted Earnings, Revenue Rise; Q3 Guidance Set - marketscreener.com
Edwards Lifesciences soars 6% on strong Q2 results, raised sales guidance - Investing.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.56%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):